CY1105750T1 - Χρηση της 1-4-(5-κυανοινδολ-3-υλο)βουτυλο-4(2-καρβαμουλοβενζοφουραν-5-υλο)πιπepαζινης και των φυσιολογικα αποδεκτων αλατων αυτης - Google Patents
Χρηση της 1-4-(5-κυανοινδολ-3-υλο)βουτυλο-4(2-καρβαμουλοβενζοφουραν-5-υλο)πιπepαζινης και των φυσιολογικα αποδεκτων αλατων αυτηςInfo
- Publication number
- CY1105750T1 CY1105750T1 CY20061101575T CY061101575T CY1105750T1 CY 1105750 T1 CY1105750 T1 CY 1105750T1 CY 20061101575 T CY20061101575 T CY 20061101575T CY 061101575 T CY061101575 T CY 061101575T CY 1105750 T1 CY1105750 T1 CY 1105750T1
- Authority
- CY
- Cyprus
- Prior art keywords
- cyanoindol
- butyl
- disorder
- physiologically acceptable
- pipepazine
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title abstract 3
- 208000008811 Agoraphobia Diseases 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 208000001640 Fibromyalgia Diseases 0.000 abstract 1
- 208000011688 Generalised anxiety disease Diseases 0.000 abstract 1
- 206010026749 Mania Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 206010041250 Social phobia Diseases 0.000 abstract 1
- 230000037328 acute stress Effects 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000029364 generalized anxiety disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 208000028173 post-traumatic stress disease Diseases 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- SGEGOXDYSFKCPT-UHFFFAOYSA-N vilazodone Chemical compound C1=C(C#N)C=C2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CNC2=C1 SGEGOXDYSFKCPT-UHFFFAOYSA-N 0.000 abstract 1
- RPZBRGFNBNQSOP-UHFFFAOYSA-N vilazodone hydrochloride Chemical group Cl.C1=C(C#N)C=C2C(CCCCN3CCN(CC3)C=3C=C4C=C(OC4=CC=3)C(=O)N)=CNC2=C1 RPZBRGFNBNQSOP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Pregnancy & Childbirth (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99109295 | 1999-05-27 | ||
| EP04001441A EP1410800B1 (en) | 1999-05-27 | 2000-05-16 | Use of 1- 4-(5-cyanoindol-3-yl)butyl -4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiologically acceptable salts |
| EP00935031A EP1185272B1 (en) | 1999-05-27 | 2000-05-16 | Novel use of 1-[4-(5-cyanoindol-3yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiological acceptable salts for the treatment of bipolar disorders and mania |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1105750T1 true CY1105750T1 (el) | 2010-12-22 |
Family
ID=8238153
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20061101575T CY1105750T1 (el) | 1999-05-27 | 2006-11-02 | Χρηση της 1-4-(5-κυανοινδολ-3-υλο)βουτυλο-4(2-καρβαμουλοβενζοφουραν-5-υλο)πιπepαζινης και των φυσιολογικα αποδεκτων αλατων αυτης |
| CY20091101063T CY1109472T1 (el) | 1999-05-27 | 2009-10-14 | Χρηση της 1-4(5-κυανοϊνδολ-3-υλο)βουτυλο-4-(2-καρβαμοϋλοβενζοφουραν-5-υλο)πιπεραζινης και των φυσιολογικα αποδεκτων αλατων αυτης |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20091101063T CY1109472T1 (el) | 1999-05-27 | 2009-10-14 | Χρηση της 1-4(5-κυανοϊνδολ-3-υλο)βουτυλο-4-(2-καρβαμοϋλοβενζοφουραν-5-υλο)πιπεραζινης και των φυσιολογικα αποδεκτων αλατων αυτης |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US6900212B1 (OSRAM) |
| EP (3) | EP1410800B1 (OSRAM) |
| JP (2) | JP4884588B2 (OSRAM) |
| KR (1) | KR100683367B1 (OSRAM) |
| CN (3) | CN1198618C (OSRAM) |
| AR (1) | AR024112A1 (OSRAM) |
| AT (3) | ATE263564T1 (OSRAM) |
| AU (1) | AU771778B2 (OSRAM) |
| BR (1) | BR0010948A (OSRAM) |
| CA (3) | CA2615271C (OSRAM) |
| CY (2) | CY1105750T1 (OSRAM) |
| CZ (1) | CZ295623B6 (OSRAM) |
| DE (3) | DE60030338T2 (OSRAM) |
| DK (3) | DK1736158T3 (OSRAM) |
| ES (3) | ES2330774T3 (OSRAM) |
| HK (1) | HK1048444B (OSRAM) |
| HU (1) | HU229059B1 (OSRAM) |
| IL (2) | IL146707A0 (OSRAM) |
| MX (1) | MXPA01012172A (OSRAM) |
| MY (1) | MY135627A (OSRAM) |
| NO (2) | NO322120B1 (OSRAM) |
| PL (3) | PL199650B1 (OSRAM) |
| PT (3) | PT1736158E (OSRAM) |
| RU (1) | RU2237477C2 (OSRAM) |
| SI (2) | SI1410800T1 (OSRAM) |
| SK (1) | SK287851B6 (OSRAM) |
| TR (1) | TR200103361T2 (OSRAM) |
| TW (1) | TW518218B (OSRAM) |
| UA (1) | UA74337C2 (OSRAM) |
| WO (1) | WO2000072832A2 (OSRAM) |
| ZA (1) | ZA200110485B (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW518218B (en) * | 1999-05-27 | 2003-01-21 | Merck Patent Gmbh | Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders |
| UA76130C2 (en) * | 2000-11-20 | 2006-07-17 | Merck Patent Gmbh | Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome |
| DE10112151A1 (de) * | 2001-03-14 | 2002-09-19 | Merck Patent Gmbh | Substituierte Benzofuran-2-carbonsäureamide |
| UA76758C2 (uk) | 2001-06-19 | 2006-09-15 | Мерк Патент Гмбх | Поліморфні форми гідрохлориду 1-'4-(5-ціаноіндол-3-іл)бутил-4-(2-карбамоїлбензофуран-5-іл)піперазину |
| DE10217006A1 (de) * | 2002-04-16 | 2003-11-06 | Merck Patent Gmbh | Substituierte Indole |
| DE10305739A1 (de) * | 2003-02-11 | 2004-08-19 | Merck Patent Gmbh | Benzofuranderivate |
| US20040192730A1 (en) * | 2003-03-13 | 2004-09-30 | Dynogen Pharmaceuticals, Inc. | Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction |
| WO2005094896A2 (en) * | 2004-03-26 | 2005-10-13 | Baylor University | Targeted serotonin reuptake inhibitors |
| CA2651663A1 (en) | 2006-05-30 | 2007-12-06 | Astrazeneca Ab | Chemical compounds |
| TW200932235A (en) | 2007-12-20 | 2009-08-01 | Astrazeneca Ab | Carbamoyl compounds as DGAT1 inhibitors |
| RU2011152517A (ru) | 2009-06-19 | 2013-07-27 | Астразенека Аб | Пиразинкарбоксамиды в качестве ингибиторов dgat1 |
| AU2010316106B2 (en) | 2009-11-06 | 2015-10-22 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating attention-deficit/hyperactivity disorder |
| CA2779442A1 (en) | 2009-11-06 | 2011-05-12 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating fibromyalgia syndrome |
| US9610274B2 (en) | 2010-06-30 | 2017-04-04 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating bipolar disorder |
| US8623913B2 (en) | 2010-06-30 | 2014-01-07 | Sk Biopharmaceuticals Co., Ltd. | Methods for treating restless legs syndrome |
| TWI577377B (zh) * | 2010-09-16 | 2017-04-11 | Ｖｉｉｖ醫療保健公司 | 醫藥組合物 |
| WO2012131706A1 (en) | 2011-03-20 | 2012-10-04 | Cadila Healthcare Limited | Amorphous form of vilazodone hydrochloride and process for its preparation |
| CN102949364A (zh) * | 2011-08-30 | 2013-03-06 | 天津药物研究院 | 一种含有效成分盐酸维拉佐酮的缓释片 |
| US9382233B2 (en) | 2012-06-13 | 2016-07-05 | Apotex Inc. | Forms of vilazodone and processes for the preparation thereof |
| CN102860993A (zh) * | 2012-10-16 | 2013-01-09 | 北京诚创思达医药科技有限公司 | 一种盐酸维拉唑酮快速释放片剂及其制备方法 |
| WO2014064715A2 (en) | 2012-10-22 | 2014-05-01 | Cadila Healthcare Limited | Amorphous form of vilazodone hydrochloride and process for preparing thereof |
| CN102977083A (zh) * | 2012-12-17 | 2013-03-20 | 南京海纳医药科技有限公司 | 1-[4-(5-氰基吲哚-3-基)丁基]-4-(2-氨甲酰-苯并呋喃-5-基)-哌嗪盐酸盐的新晶型xⅶ及其制备方法 |
| RS59687B1 (sr) | 2013-01-22 | 2020-01-31 | Vistagen Therapeutics Inc | Oblici doziranja i terapeutske primene l-4-hlorkinurenina |
| EP2824104A1 (en) | 2013-07-12 | 2015-01-14 | Sandoz AG | Process for the preparation of form III of Vilazodone hydrochloride |
| CN107949379A (zh) * | 2015-05-22 | 2018-04-20 | 维斯塔津治疗公司 | L‑4‑氯代犬尿氨酸的治疗用途 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2672052B1 (fr) * | 1991-01-28 | 1995-05-24 | Esteve Labor Dr | Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments. |
| SE9201239D0 (sv) * | 1992-04-21 | 1992-04-21 | Kabi Pharmacia Ab | Agents for treating substance abuse disorders |
| DE4333254A1 (de) * | 1993-09-30 | 1995-04-06 | Merck Patent Gmbh | Piperidine und Piperazine |
| GB9406857D0 (en) * | 1994-04-07 | 1994-06-01 | Sandoz Ltd | Improvements in or relating to organic compounds |
| DE19514567A1 (de) * | 1995-04-20 | 1996-10-24 | Merck Patent Gmbh | Benzofurane |
| US5763457A (en) * | 1995-11-13 | 1998-06-09 | Eli Lilly And Company | Method for treating anxiety |
| US5914394A (en) * | 1997-03-27 | 1999-06-22 | Millenium Pharmaceuticals, Inc. | Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders |
| US5900420A (en) * | 1997-06-19 | 1999-05-04 | Cole; William L. | Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine |
| US6470933B1 (en) * | 1998-03-09 | 2002-10-29 | Pirelli Pneumatici S.P.A. | Tire containing at least part of an electrical current generator intended for the supply of sensors and/or other electrical devices present within the tire, and method for manufacture the said tire |
| FR2781671A1 (fr) * | 1998-07-28 | 2000-02-04 | Synthelabo | Compositions pharmaceutiques contenant un inhibiteur de la recapture de la serotonine et leur application en therapeutique |
| TW518218B (en) * | 1999-05-27 | 2003-01-21 | Merck Patent Gmbh | Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders |
| EP1612564A3 (en) * | 2001-09-11 | 2009-12-09 | JTEKT Corporation | Magnetic pulser ring |
| FR2844591B1 (fr) * | 2002-09-13 | 2005-04-15 | Arvinmeritor Light Vehicle Sys | Dispositif de determination du deplacement d'un arbre |
-
1999
- 1999-11-15 TW TW088119882A patent/TW518218B/zh not_active IP Right Cessation
-
2000
- 2000-05-16 MX MXPA01012172A patent/MXPA01012172A/es active IP Right Grant
- 2000-05-16 UA UA2001128861A patent/UA74337C2/uk unknown
- 2000-05-16 PT PT06017231T patent/PT1736158E/pt unknown
- 2000-05-16 EP EP04001441A patent/EP1410800B1/en not_active Expired - Lifetime
- 2000-05-16 ES ES06017231T patent/ES2330774T3/es not_active Expired - Lifetime
- 2000-05-16 PT PT04001441T patent/PT1410800E/pt unknown
- 2000-05-16 CZ CZ20014226A patent/CZ295623B6/cs not_active IP Right Cessation
- 2000-05-16 AU AU50663/00A patent/AU771778B2/en not_active Ceased
- 2000-05-16 DK DK06017231T patent/DK1736158T3/da active
- 2000-05-16 ES ES04001441T patent/ES2271707T3/es not_active Expired - Lifetime
- 2000-05-16 RU RU2001133342A patent/RU2237477C2/ru not_active IP Right Cessation
- 2000-05-16 CN CNB008081352A patent/CN1198618C/zh not_active Expired - Fee Related
- 2000-05-16 DK DK04001441T patent/DK1410800T3/da active
- 2000-05-16 CA CA2615271A patent/CA2615271C/en not_active Expired - Fee Related
- 2000-05-16 EP EP00935031A patent/EP1185272B1/en not_active Expired - Lifetime
- 2000-05-16 US US09/979,922 patent/US6900212B1/en not_active Expired - Lifetime
- 2000-05-16 BR BR0010948-7A patent/BR0010948A/pt not_active Application Discontinuation
- 2000-05-16 DE DE60030338T patent/DE60030338T2/de not_active Expired - Lifetime
- 2000-05-16 IL IL14670700A patent/IL146707A0/xx active IP Right Grant
- 2000-05-16 DK DK00935031T patent/DK1185272T3/da active
- 2000-05-16 JP JP2000620944A patent/JP4884588B2/ja not_active Expired - Fee Related
- 2000-05-16 PL PL383406A patent/PL199650B1/pl unknown
- 2000-05-16 CA CA2694866A patent/CA2694866A1/en not_active Abandoned
- 2000-05-16 ES ES00935031T patent/ES2219342T3/es not_active Expired - Lifetime
- 2000-05-16 TR TR2001/03361T patent/TR200103361T2/xx unknown
- 2000-05-16 AT AT00935031T patent/ATE263564T1/de active
- 2000-05-16 HU HU0201275A patent/HU229059B1/hu not_active IP Right Cessation
- 2000-05-16 AT AT06017231T patent/ATE438399T1/de active
- 2000-05-16 SK SK1646-2001A patent/SK287851B6/sk not_active IP Right Cessation
- 2000-05-16 HK HK03100617.0A patent/HK1048444B/zh not_active IP Right Cessation
- 2000-05-16 KR KR1020017015141A patent/KR100683367B1/ko not_active Expired - Fee Related
- 2000-05-16 CN CN200910113677A patent/CN101869565A/zh active Pending
- 2000-05-16 PL PL352373A patent/PL199516B1/pl unknown
- 2000-05-16 EP EP06017231A patent/EP1736158B1/en not_active Expired - Lifetime
- 2000-05-16 SI SI200030902T patent/SI1410800T1/sl unknown
- 2000-05-16 DE DE60009697T patent/DE60009697T2/de not_active Expired - Lifetime
- 2000-05-16 PL PL383006A patent/PL200490B1/pl unknown
- 2000-05-16 SI SI200030423T patent/SI1185272T1/xx unknown
- 2000-05-16 CN CNA2005100544177A patent/CN1679577A/zh active Pending
- 2000-05-16 WO PCT/EP2000/004376 patent/WO2000072832A2/en not_active Ceased
- 2000-05-16 CA CA002372668A patent/CA2372668C/en not_active Expired - Fee Related
- 2000-05-16 DE DE60042710T patent/DE60042710D1/de not_active Expired - Lifetime
- 2000-05-16 PT PT00935031T patent/PT1185272E/pt unknown
- 2000-05-16 AT AT04001441T patent/ATE337008T1/de active
- 2000-05-25 MY MYPI20002314A patent/MY135627A/en unknown
- 2000-05-26 AR ARP000102575A patent/AR024112A1/es unknown
-
2001
- 2001-11-22 IL IL146707A patent/IL146707A/en not_active IP Right Cessation
- 2001-11-26 NO NO20015746A patent/NO322120B1/no not_active IP Right Cessation
- 2001-12-20 ZA ZA200110485A patent/ZA200110485B/en unknown
-
2004
- 2004-11-23 US US10/994,226 patent/US7371756B2/en not_active Expired - Lifetime
-
2006
- 2006-04-06 NO NO20061562A patent/NO324230B1/no not_active IP Right Cessation
- 2006-11-02 CY CY20061101575T patent/CY1105750T1/el unknown
-
2007
- 2007-11-28 US US11/946,149 patent/US7642261B2/en not_active Expired - Fee Related
-
2009
- 2009-10-14 CY CY20091101063T patent/CY1109472T1/el unknown
- 2009-11-17 US US12/620,049 patent/US20100063062A1/en not_active Abandoned
-
2011
- 2011-02-10 JP JP2011027903A patent/JP2011148799A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1105750T1 (el) | Χρηση της 1-4-(5-κυανοινδολ-3-υλο)βουτυλο-4(2-καρβαμουλοβενζοφουραν-5-υλο)πιπepαζινης και των φυσιολογικα αποδεκτων αλατων αυτης | |
| DE69424893D1 (de) | Enantiomere von 1-[(4-Chlorophenyl)phenylmethyl]-4-[(4-Methylphenyl)sulfonyl]piperazin | |
| RU2001133342A (ru) | Новое применение 1[4-(5-цианоиндол-3-ил)бутил]-4-(2-карбамоилбензофуран-5-ил)-пиперазина и его физиологически приемлемых солей | |
| DE60103927D1 (de) | Piperazin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems | |
| ATE420866T1 (de) | 4-(phenylpiperazinylmethyl) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen | |
| EE05454B1 (et) | 1-[4-(5-tsanoindool-3-l)butl]-4-(2-karbamolbensofuraan-5-l)piperasiinvesinikkloriidi polmorfsed vormid, nende valmistamismeetodid ja neid sisaldavad farmatseutilised kompositsioonid | |
| ATE188691T1 (de) | 1-(1,2-disubstituierte piperidinyl)-4- substituierte piperazin derivate | |
| ATE447561T1 (de) | Substituierte aryl 1,4-pyrazin derivate | |
| DK1445249T3 (da) | Nye bensophenon-derivater eller salte deraf | |
| IS7271A (is) | Piperdine og piperazine afleiður 2,4-disubstituted, 3,5-disubstituded and 3,4,5-sumstituted piperadines and piperazines | |
| DK0810991T3 (da) | 1-Aryl-2-acylamino-ethan-forbindelser og deres anvendelse som neurokinin- især neurokinin-1-antagonister | |
| DE60205894D1 (de) | 4-(phenyl-piperidin-4-ylidenmethyl)-benzamid-derivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen | |
| EE200100498A (et) | 1,4-asendatud piperasiin-, 1,4-asendatud piperidiin- ja 1-asendatud 4-alkülidenüülpiperidiinühendidning nende raviotstarbeline kasutamine | |
| DE60328901D1 (de) | Verfahren zur herstellung von 4-(3'-chlor-4'-fluoranilino)-7-methoxy-6-(3-morpholinopropoxy)chinazolin | |
| ATE313528T1 (de) | 4-(phenyl(piperidin-4-yl)amino) benzamidderivate und deren verwendung zur behandlung von schmerzen,angst oder gastrointestinalen störungen | |
| BR0316126A (pt) | Combinação de compostos para o tratamento de leucemia linfocìtica crÈnica | |
| ATE287400T1 (de) | 4-(phenylpiperidin-4-ylidenmethyl) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen | |
| DE60208193D1 (de) | 4-(phenyl(piperidin-4-yl)amino) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen | |
| DK451884D0 (da) | 2-(n-pyrrolidino)-3-isobutoxy-n-substituerede phenyl-n-benzyl-propylaminer, deres fremstilling og farmaceutiske anvendelse | |
| DE50210727D1 (de) | Verwendung von arzneimitteln enthaltend n, n'-disubstituierte piperazin-verbindungen | |
| DE602004022540D1 (de) | Verwendung von tyrosin-kinase-hemmern zur behandlung von diabetes | |
| ATE356806T1 (de) | Salze von amlodipin-mesylat | |
| DE602004022635D1 (de) | Verwendung von naringenin, naringin und salzen daraus als schleimlöser bei der behandlung von husten sowie zusammensetzungen daraus | |
| DE60223793D1 (de) | Titaniumkatalysatoren, herstellung, und verwendung in ko- und ter-polymerisation von alpha-olefinen |